Real-world data (RWD) is transforming clinical research, augmenting existing randomized controlled trial (RCT) data to de-risk studies and improve generalizability. With regulators setting clearer ...
In his post, Makary said, “FDA will take swift action against companies’ mass-marketing illegal copycat drugs, claiming they ...
After months of speculation, TrumpRx is live and offering Americans a variety of important medications at most-favored-nation ...
FDA has approved Vybrique, the first oral film formulation of sildenafil for the treatment of erectile dysfunction, offering ...
The FDA rejected AstraZeneca's subcutaneous Saphnelo application, delaying U.S. approval until 2026, despite positive ...
SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...
In a lean biotech environment with aggressive milestones, teams often accept reporting that is “good enough.” But those ...
In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application ...
Eli Lilly is investing $3.5 billion in a new manufacturing facility in Lehigh Valley, Pennsylvania, to produce injectable ...
In today’s Pharmaceutical Executive Daily, FDA approves Vybrique for erectile dysfunction, experts argue Phase III clinical ...
In today’s Pharmaceutical Executive Daily, Susan G. Komen releases its 2026 breast cancer progress outlook, industry leaders ...
PE: After presenting topline results from Phase 3 trials, what's next for Varegacestat? Siegall: We presented topline data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results